Thus, decreased level of HSPA5/GRP78 may be investigated in future clinical studies as a clinical endpoint to monitor and/or predict treatment efficacy in BRAFV600E-mutated colon cancer patients. Here, HSPA5 is linked to colonic neoplasm.